RecruitingPhase 2NCT05972135
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Studying Multiple myeloma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SCRI Development Innovations, LLC
- Principal Investigator
- Peter A. Forsberg, MD, PA-CSCRI Development Innovations, LLC
- Intervention
- Teclistamab(drug)
- Enrollment
- 100 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (17)
- Arizona Oncology Associates, Tucson, Arizona, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- Rocky Mountain Cancer Center, Denver, Colorado, United States
- Medical Oncology Hematology Consultants, Newark, Delaware, United States
- Florida Cancer Specialists, Lake Mary, Florida, United States
- Maryland Oncology Hematology, Columbia, Maryland, United States
- Minnesota Oncology Hematology, Minneapolis, Minnesota, United States
- Virginia Oncology Associates, Elizabeth City, North Carolina, United States
- Oncology Hematology Care, Cincinnati, Ohio, United States
- Oncology Associates of Oregon, Eugene, Oregon, United States
- TriStar Bone Marrow Transplant, Nashville, Tennessee, United States
- Vanderbilt- Ingram Cancer Center, Nashville, Tennessee, United States
- Texas Oncology, Austin, Texas, United States
- Texas Oncology - San Antonio, San Antonio, Texas, United States
- Texas Oncology - Northeast Texas, Tyler, Texas, United States
- +2 more locations on ClinicalTrials.gov
Collaborators
Johnson & Johnson
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05972135 on ClinicalTrials.govOther trials for Multiple myeloma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07225738A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma PatientsCity of Hope Medical Center
- RECRUITINGPHASE3NCT06980480A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaTakeda
- RECRUITINGPHASE4NCT07094048Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell EngagerCHU de Quebec-Universite Laval
- RECRUITINGNANCT07226934An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersWashington University School of Medicine
- RECRUITINGEARLY PHASE1NCT07294625A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1NCT07179679A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06514508Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsGuangzhou Gloria Biosciences Co., Ltd.
- RECRUITINGNANCT07359014Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple MyelomaSecond Affiliated Hospital, School of Medicine, Zhejiang University